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Abstract
Background: The burden of acute coronary syndrome (ACS) and heart failure (HF) remains high in Saudi Arabia.
Biomarkers can greatly improve the management and outcomes of these conditions, but no ofﬁcial guidance is available
on their use in Saudi Arabia.
Consensus panel: An expert panel of cardiologists, interventional cardiologists and cardiac surgeon reviewed available
evidence and formulated recommendations relevant to clinical practice in Saudi Arabia.
Consensus ﬁndings: high-sensitivity cardiac troponins play a major role in the diagnosis of ACS and the exclusion of
myocardial infarction in patients with HF. Natriuretic Peptides are recommended to determine the likelihood of a
diagnosis of HF in a chronic setting and rapidly exclude HF in an acute setting. High-sensitivity cardiac troponins and
NT-proBNP have good prognostic ability in ACS and HF. These biomarkers could also facilitate discharge planning and
reduce unnecessary hospital admissions and resource wastage. The use of biomarkers should not be excessive and
should abide by appropriateness criteria. High-sensitivity assays and NT-proBNP measurements are preferred.
Conclusion: By outlining expert recommendations on the best practices in the use of biomarkers, the panel hopes to
contribute towards a recognized updated guidance for all healthcare providers in Saudi Arabia on the evidence-based
management of HF and ACS.
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1. Introduction

D

espite the availability of advanced guidelines
for the management of both heart failure (HF)
and acute coronary syndrome (ACS), these conditions continue to carry a signiﬁcant burden in terms

of morbidity and mortality in the Kingdom of Saudi
Arabia (KSA). National awareness campaigns, primary prevention programs and appropriate policy
changes are urgently needed to promote adherence
and curb the rise in the prevalence and mortality of
heart disease [1,2]. In fact, the prevalence of unhealthy lifestyles and cardiovascular disease (CVD)
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risk factors (diabetes, dyslipidemia, hypertension,
obesity, smoking) continues to be alarmingly high in
the general adult Saudi populations [3]. These
exacerbating factors are clearly reﬂected in patients
with acute or chronic HF [4,5], as well as those with
ACS [6,7]. Age of HF and ACS onset is relatively low
in the KSA compared to western countries. 44.7% of
patients with acute HF were found to have a history
of chronic HF [4], while mean age of ACS patients
was 58 years old [7]. Evidence from the HEARTS
registry shows that chronic HF patients not only
present at younger ages, but also exhibit relatively
high mortality and re-hospitalization rates [4,5]. The
SPACE registry revealed delayed initiation of
thrombolytic therapy or primary percutaneous coronary intervention [7]. Moreover, around 28% of
patients with acute HF have concomitant ACS and
subsequently have worse hospital prognosis [8].
Timely recognition and management of both HF
and ACS is therefore crucial.
The cardiac troponin complex is composed of
three distinct proteins, of which cardiac troponin T
(cTnT) and cardiac troponin I (cTnI) are expressed
almost exclusively in cardiac muscle. cTnT and cTnI
are released by the heart following myocyte damage
and can be detected in the blood, which prompted
their use as reliable and speciﬁc markers of
myocardial injury. Of atrial natriuretic peptides
(ANPs), B-type natriuretic peptide (BNP) is initially
synthesized as proBNP, which is then cleaved into
the active peptide hormone (BNP) and the inactive
N-terminal fragment (NT-proBNP). These biomarkers are also secreted in response to cardiac
hemodynamic stress, and are consequently used in
the primary prevention of heart disease. The main
objective of this position statement is to assist cardiologists, internal medicine specialists and emergency department personnel in the KSA to better
diagnose and treat HF and ACS through sharing the
key opinion leaders’ best practices on the use of
biomarkers. This project can be a step forward towards a recognized updated guidance for all
healthcare providers in the KSA on the evidencebased management of HF and ACS.

2. Methods
In a meeting held virtually in January 2022, 8 experts representing the Saudi Heart Association
(SHA) reviewed current evidence and guidelines
regarding the use of biomarkers for the management of HF and ACS. Expert opinion was gathered
on each topic and synthesized into position statements formulated speciﬁcally to reﬂect Saudi
healthcare needs, resources and practice.
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Abbreviations
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BNP
COVID-19
cTn
CVD
ECG
GDF-15
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h-FABP
Hs-CRP
Hs-cTn
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MR-proADM
MR-proANP
NT-proBNP
PCI
SHA

Acute coronary syndrome
Atrial natriuretic peptides
B-type natriuretic peptide
Coronavirus disease 2019
Cardiac troponins
Cardiovascular disease
Electrocardiogram
Growth Differentiation Factor 15
Heart failure
Heart-type fatty acid binding protein
High sensitivity C reactive protein
High-sensitivity cTn (Hs-cTn)
Kingdom of Saudi Arabia
Mid-regional proadrenomedullin
Mid-regional pro-atrial natriuretic peptide
N-terminal fragment B-type natriuretic
peptide
Percutaneous coronary intervention
Saudi Heart Association

3. Results - consensus statements
3.1. Acute coronary syndrome (ACS)
a) Diagnosis of ACS

Position statement: Diagnosis
Diagnosis and initial short-term risk stratification
should be founded on a combination of clinical history,
physical findings (symptoms, vital signs, others), electrocardiogram (ECG), and laboratory results (i.e. highsensitivity cardiac troponin).
The measurement of cardiac troponins is recommended
with high-sensitivity assays. Measurement should be
done as soon as possible at admission and time to
obtaining test results should not exceed 60 minutes
since blood sampling.
Obtaining a second blood sample is recommended
within 2 hours of admission, although it is also
reasonable to obtain a second sample within 1 or 3
hours of admission.
If the first two consecutive samples are inconclusive or
if the clinical situation is uncertain, cardiac troponins
should be measured for the third time to determine
whether the diagnosis of ACS is unlikely.
While cardiac troponin can be detected in healthy
individuals, the rise and fall or cardiac troponin
levels allow the differentiation between acute cardiomyocyte damage, such as myocardial infarction,
and chronic damage [9]. high-sensitivity cTn (Hs-

SHA RECOMMENDATIONS

JOURNAL OF THE SAUDI HEART ASSOCIATION 2022;34:114e123

116

JOURNAL OF THE SAUDI HEART ASSOCIATION 2022;34:114e123

SHA RECOMMENDATIONS

cTn) levels are quantitative markers of cardiomyocyte damage; the likelihood of myocardial
infarctions increases along with elevation of hs-cTn
levels [9]. The highest positive predictive value is
observed with elevations of hs-cTn exceeding 5-fold
the upper reference limit [9]. When compared to
standard cardiac troponin assays, hs-cTn assays
were shown to be more cost effective and have
higher negative predictive value for acute myocardial infarction, as well as ensure earlier and higher
detection of acute myocardial infarction and both
type 1 and type 2 myocardial infarction [9e13].
Moreover, the diagnostic accuracy of hs-cTn assays
is not compromised in patients with renal dysfunction and myocardial injury can be ruled out at assayspeciﬁc thresholds [14]. Rigorous quality speciﬁcations are set forth by international guidelines for
immunoassays to be considered ‘high-sensitivity”,
leading to a notable increase in the analytical performance of immunoassay methods [15]. For
example, the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers (Academy of AACC
and Task Force of IFCC) suggested in 2017 that cTn
assays are “guideline acceptable” if they can measure the 99th URL value with a % CV of 10,
“clinically useable” if the % CV is > 10 to 20, and
“not clinically acceptable” if the % CV is > 20 (for
detailed information, see Ref. [16]). To note while
both cTnT and cTnI carry high diagnostic and
prognostic value [17], cutoff points are assay-speciﬁc
for cTnT and cTnI owing to their distinct biological
properties and the differences in the commercial
immunoassays used for their detection. These differences should be carefully considered when
interpreting results to ensure accurate interpretation of cTnT and cTnI levels (Table 1).
Hs-cTn (either T or I) should be measured
immediately upon admission, with repeat testing
recommended within 2 hours (±1 hour). Results
should be obtained within 60 minutes of blood
draw. Diagnosis should be based on available clinical information (history, signs, symptoms,

electrocardiogram (ECG), laboratory results) in
addition to the use of hs-cTn [9,18].
Cardiac troponins should not be measured in all
patients presenting to the emergency room with
chest pain. Elevated troponin levels are observed in
cardiac pathologies other than ACS (i.e. Tachyarrhythmias, heart failure, hypertensive emergencies,
critical illness, myocarditis) as well as non-cardiac
conditions (i.e. renal impairment in the elderly, acute
neurologic event) and should be carefully considered
as differential diagnoses. Studies show that about
half of troponins ordered in the emergency room
were not appropriate [19,20]. Emergency personnel
and cardiologists have different perceptions of clinically appropriate use of cTn testing, with broader
appropriateness perceived by emergency personnel
[21]. In order to avoid overuse of cTn measurement,
testing should only be undertaken when appropriate
(see appropriateness criteria).
Position statement: cTn measurement appropriateness criteria
- Patients who present with consistent chest pain/
discomfort without relief for at least 30 minutes
- Patients who present with acute shortness of breath,
collapse of unknown origin
- Patients with diabetes who present with history of
weakness, shortness of breath collapse with or
without chest pain/discomfort
- Unclear ECG (for confirmation of myocardial
infarction)
- Arrythmias
- Patients with ischemic ECG changes
- New or presumed new left bundle branch block
(LBBB) on ECG
* cTn testing is not required for patients diagnosed with
ST-elevation myocardial infarction and who are treated
promptly (unless requested by cardiologist).
* Patients with no CAD risk factors and cTnT < 14 ng/
L or equivalent assay-specific cTnI levels (see Table 1)
do not require repeat testing.

Table 1. Assay speciﬁc cut-off levels for cTnT and cTnI.
Assay

hs-cTn
hs-cTn
hs-cTn
hs-cTn
hs-cTn
hs-cTn
hs-cTn
hs-cTn

Cutoff level (ng/L)

T (Elecsys; Roche)
I (Architect; Abbott)
I (Centaur; Siemens)
I (Access; Beckman Coulter)
I (Clarity; Singulex)
I (Vitros; Clinical Diagnostics)
I (Pathfast; LSI Medience)
I (TriageTrue; Quidel)

b) Prognosis

Very low

Low

High

<5
<4
<3
<4
<1
<1
<3
<4

<14
<6
<8
<5
TBD
TBD
TBD
TBD

52
64
120
50
30
40
90
60

Position statement: Prognosis
cTn levels are useful for prognosis.
High-sensitivity cTn is favored as a biomarker in cases
of acute chest pain upon presentation due to its more

rapid detection/exclusion of myocardial injury and
higher diagnostic accuracy.
BNP or NT-proBNP plasma concentration measurement should also be considered.
Other biomarkers (MR-proANP, hs-CRP, MRproADM, GDF-15, copeptin, and h-FABP) are not
currently recommended for prognosis or risk
assessment.
While there is currently not enough evidence to
support the use of biomarkers such as mid-regional
pro-atrial natriuretic peptide (MR-proANP), high
sensitivity C reactive protein (hs-CRP), Midregional
proadrenomedullin
(MR-proADM),
Growth Differentiation Factor 15 (GDF-15), copeptin, and heart-type fatty acid binding protein (hFABP) for prognosis in ACS, cTn is an important
prognostic factor in this setting. Elevated troponins
in the general population were found to be most
strongly correlated with fatal cardiovascular disease,
including coronary heart disease and stroke [22].
Patients with chest pain and no myocardial infarction commonly exhibit cTn levels higher than the
99th percentile [23]. A higher risk of death and
adverse cardiovascular outcomes is associated with
detectable cTn among patients with chest pain and
no myocardial infarction or unstable troponin levels
[24]. There is also evidence to support the preoperative predictive value of BNP and NT-proBNP in
the context of adverse outcomes after cardiac surgery [25]. NT-proBNP was also shown to have good
predictive value for 30-day mortality in patients with
non-ST-elevation ACS [26]. BNP or NT-proBNP as
well as troponin can also enhance the performance
of cardiac risk indexes in predicting major adverse
cardiac events [25].
Postoperative changes in hs-cTnT concentrations
have been shown to be useful for detecting the risk
of perioperative myocardial infarction, major
adverse events or mortality. Post-percutaneous
coronary intervention (PCI) peak cTn levels was
associated with a 7% increase in mortality after 1
year [27]. Similarly, peak post-procedural cTn was
correlated with 3-year mortality after early PCI in
non-ST-elevation myocardial infarction patients [28]
and independently associated with clinical outcomes and cardiac function 3 months after PCI for
ST-elevation myocardial infarction [29]. Post-PCI
cTn levels are therefore Pre-PCI cTn levels could
also be important to understand the variations of
this biomarker post-PCI and their prognostic value
[30]. Elevations of troponin levels within the ﬁrst
day of CABG were also predictive of intermediate
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and long-term mortality [31]. In fact, peak hs-TnT
level >400 ng/L within 24 hours post-CABG is
associated with major adverse cardiac or cerebrovascular event, 30-day mortality, myocardial
infarction and intensive care unit stay longer than 2
days [32,33].
Elevated troponin levels are also one of the hallmarks of viral myocarditis [34], and are detected in
most patients with viral illnesses associated with
myocardial injury, such as coronavirus disease 2019
(COVID-19) [35]. Patients who had severe infections,
who were admitted to the intensive care unit or who
have died from COVID-19 had signiﬁcantly higher
levels of cTn [36].
c) Resource use

Position statement: health outcomes
Cardiac troponins can be used for the early exclusion of
myocardial infarction, which could subsequently reduce
hospital admissions for serial cardiac biomarker testing
and unnecessary use of resources.

The implementation of hs-cTn testing can lead to
improved detection of ACS and unstable angina
[37]. The introduction of hs-cTn ensures a better
rule-out process in the emergency department,
thereby reducing the need for stress testing and
decreasing time to discharge without increasing the
use/inappropriate use of coronary angiography [38].
The use of high sensitivity cTn testing has positive
organizational value seeing as it leads to reduced
cost, improved referral to the appropriate department and reduced hospital length of stay in patients
with suspected ACS [39].

3.2. Heart failure (HF)
a) Detection of high-risk patients and prevention of
HF
Position statement: Prevention of HF
For patients at high risk of cardiac injury (e.g. diabetic
patients, patients receiving chemotherapy), screening
with biomarkers (NT-proBNP and high sensitivity cTn)
can be helpful to prevent the development of HF.
NT-proBNP was strongly associated with ﬁrst
onset HF and can improve the prediction of strokes
and coronary heart disease in the absence of
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baseline cardiovascular disease [40]. High sensitivity cTn was also shown to play a role in risk
stratiﬁcation for new onset HF as well as the prediction of HF [41]. These biomarkers are also useful
in special populations, with both NPs and troponin
showing beneﬁt for the early detection of cardiac
dysfunction in cancer patients at risk of cardiotoxicity [42,43]. Troponin is more sensitive than BNP
for the detection of subclinical cardiotoxicity in the
context of chemotherapy and elevated cTn levels
are actually an indicator to initiate therapy with
angiotensin-converting enzyme inhibitors [42e44].
NT-proBNP levels can also predict cardiovascular
outcomes, HF, and HF-related hospitalization in
patients with type 2 diabetes mellitus [45]. Both
BNP and NT-proBNP were also demonstrated as
strong predictors of cardiovascular morbidity and
mortality in diabetic patients with recent ACS [46].
The PONTIAC I trial results were indicative that
the primary prevention of cardiac events among
diabetic patients can safely incorporate NTproBNP for patient selection for therapy up-titration [47]. It is therefore the experts’ opinion that
biomarker-based screening should be incorporated
into standard practice to assist in efforts for the
primary prevention of HF. NT-proBNP and highsensitivity cTn are the preferred biomarkers.
Screening should be conducted annually in the
absence of an alarming change in clinical status.
Patients receiving chemotherapy should be monitored every 3 months until the end of treatment,
after which the screening frequency can be
decreased to once yearly. It is important to note
that while the measurement of NT-proBNP and
BNP levels can be achieved through different
techniques and commercially available assays, the
results obtained are not interchangeable. The differences in diagnostic cutoff levels emphasizes the
importance of monitoring all HF patients using the
same assay (BNP or NT-proBNP) [48]. While the
pathophysiological and clinical characteristics of
NPs and cTn are different, they remain complementary and their measurement offers valuable
insights into cardiac dysfunction and/or cardiomyocytes damage. As previously mentioned,
increased levels of NPs reﬂect alterations in cardiac
function and cardiac stress, and increases in hs-cTn
(I and T) indicate myocardial injury [49]. Combined
measurement of NP and cTn can therefore be
useful for the evaluation of cardiovascular risk in
patients with cardiac disease, as well as the general
population [50,51].

b) Diagnosis of chronic and acute HF
Chronic HF
Position statement: Diagnosis of chronic HF
Measurement of NPs is recommended to determine the
likelihood of a diagnosis of HF.
HF can be ruled out (further testing not necessary) at a
plasma concentration of B-type natriuretic peptide
(BNP) <35 pg/mL, or N-terminal pro-B-type natriuretic
peptide (NT-proBNP) <125 pg/mL.
NP should be evaluated as an essential test before
echocardiography to avoid delay in diagnosis and
reduce unnecessary echocardiographs. An NTproBNP cut-off of 125 pg/mL exhibits high sensitivity and negative predictive value for HF diagnosis
[52]. A diagnosis of HF can be effectively ruled out
when NT-proBNP levels are below the threshold
[53]. Some evidence suggests that the diagnostic
accuracy of BNP and NT-proBNP is similar [54],
while others report higher speciﬁcity and sensitivity
with NT-proBNP [55,56]. MR-proANP has diagnostic value in chronic HF similar to NT-proBNP
[57]. However, it is not available in the KSA and will
therefore not be considered in this position statement. Available evidence shows that evaluation of
NPs is essential for the prevention of misdiagnosis
or diagnosis delays. Ensuring the availability of NTproBNP in primary care leads to improvement of
care and reduces healthcare costs through the
reduction of resource wastage.
Acute HF
Position statement: diagnosis of acute HF
In the acute setting, measurement of NPs and serum
troponin is recommended to rapidly exclude the diagnosis of acute HF and reduce resource wastage.
Acute HF can be ruled out (further testing not necessary) at a plasma concentration of B-type natriuretic
peptide (BNP) <100 pg/mL, or N-terminal pro-B-type
natriuretic peptide (NT-proBNP) <300 pg/mL.
If the diagnosis of acute HF is likely (B-type natriuretic
peptide (BNP) 100 pg/mL, or N-terminal pro-B-type
natriuretic peptide (NT-proBNP) 300 pg/mL), proceed to other diagnostic modalities to confirm the
diagnosis.

In the context of suspected acute HF, plasma
NPs (BNP or NT-proBNP) should be measured
upon presentation to help rule out the diagnosis.
BNP or NT-proBNP levels below the cut-offs (<100
pg/mL for BNP, <300 pg/mL for NT-proBNP)
greatly reduce the likelihood of diagnosing acute HF
[58,59]. While NPs allow emergency personnel to
strongly exclude acute HF and avoid unnecessary
testing, their positive predictive value falls short of
their negative predictive value. Moreover, other
non-cardiac conditions (i.e. cancer, concomitant
atrial ﬁbrillation and/or reduced renal function) can
lead to elevated NP levels [59e61]. Patients presenting with BNP >100 pg/mL or NT-proBNP >300
pg/mL should therefore be subjected to further
diagnostic tests, such as ECG, echocardiography
and chest X-ray. This approach would not only help
conﬁrm/exclude the diagnosis of acute HF, but
would also reduce healthcare cost by preventing the
need for imaging all patients suspected of acute HF
[62].
c) Prognostication in heart failure
Position statement: Prognostication in HF
Baseline NP biomarkers and/or cardiac troponin could
be measured to establish prognosis in both acute HF
(upon hospital admission) and chronic HF (at
presentation).
In addition to ruling out the diagnosis of HF,
elevated serum NPs can shed valuable insights into
patient prognosis. Elevated NT-proBNP levels at
admission are independently and positively associated with cardiovascular mortality and all-cause
mortality in patients with acute decompensated
heart failure [63]. BNP and NT-proBNP have similar
prognostic value in chronic HF on the level of
mortality (all-cause, cardiovascular, HF mortality)
[64] and HF-related hospitalization [65]. Serum
troponin T levels can also serve for the early prediction of short-term outcomes such as 28-day
mortality in acute HF [66]. In the context of chronic
HF, hs-cTnT strongly predicts mortality (all-cause
and cardiovascular), in addition to cardiovascularrelated hospitalization [67,68].
d) Discharge planning
Position statement: Discharge planning in HF
NP measurements pre-discharge should be considered
for discharge planning and patient follow-up.
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Serum NPs can also be predictive of outcomes
after hospitalization and could therefore inform
discharge planning. Changes in NT-proBNP levels
from admission to discharge as well as absolute
value of NT-proBNP at discharge carry prognostic
value and can predict adverse events [69]. Discharge
risk models including NT-proBNP are strongly
predictive of all-cause mortality, cardiovascular
events, as well as 30-days readmission or death
[69e71].
e) Outpatient prognostication
Position statement: Outpatient prognostication
NT-proBNP measurements (NT-proBNP threshold
1000 pg/mL) might be useful for outpatient prognostication, taking into consideration biological variability
of NP levels (e.g. gender, age, BMI, renal function,
comorbidities, medication).
NT-proBNP 1000 pg/mL was validated as a
threshold of risk of subsequent cardiovascular
events [72,73]. Patients with baseline NT-proBNP
>1000 pg/mL who achieve NT-proBNP levels below
this threshold have approximately 60% less risk of
HF hospitalization and cardiovascular death [74].
Reduction of NT-proBNP levels is associated with
greater cardiac remodeling, improved clinical outcomes and better quality of life [73,75,76]. That being
said, it is important to take into consideration the
biological variation of NP levels according to age,
gender, body mass index, cardiac and non-cardiac
conditions, and renal function [77]. It is also crucial
to account for the effect of therapy on NP levels.
Speciﬁcally, caution should be exercised in the
interpretation of elevated BNP values in patients
receiving angiotensin receptor-neprilysin inhibitors
(ARNis), in which case NT-proBNP measurement
might be preferable [78]. In this regard, clinicians
should therefore be aware of the seemingly contradictory clinical variations of NPs and their implications to clinical practice. The levels of the active
peptide hormone BNP depend on the in vivo enzymatic cleavage of the proBNP precursor by plasma
proteases, which have different mechanisms of action on the inactive peptide NT-proBNP. Studies
have made it evident that ARNIs can selectively
inhibit natriuretic peptide degradation, causing an
increase in the circulating levels of BNP, a substrate
of neprilysin, while concomitantly reducing the
levels of NT-proBNP (which is not a substrate of
neprilysin). As such, decreases in NT-proBNP levels
in the ﬁrst days of treatment with ARNI can be
interpreted as an indication of favourable
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myocardial and vascular outcomes with treatment,
and increases in BNP levels reﬂect the inhibiting
effects of the drug or clinical deterioration due to
failure of treatment [79].
f) Treatment
Position statement: Treatment
The choice and up-titration of therapy is not dependent
on NPs and treatment should be planned regardless of
NP levels.
NT-proBNP guide therapy was not associated
with improvement in HF outcomes among highrisk HF patients with reduced ejection fraction in
the GUIDE-IT trial when compared to usual care
[80], nor among chronic HF patients in general
[81,82]. This is in contrast with an earlier trial
where the use of NT-proBNP to guide the treatment of HF patients with left ventricular systolic
dysfunction led to improved outcomes and quality
of life [73]. Regardless, the routine measurement of
BNP or NT-proBNP cannot be recommended to
guide therapy choice or titration. For guidance on
patient management, refer to the latest SHA HF
guidelines.

4. Conclusion
The burden of ACS and HF continues to be signiﬁcant in Saudi Arabia. The appropriate use of
biomarkers can not only improve the diagnosis and
prognostication of these conditions, but also reduce
unnecessary hospitalizations and resource wastage.
Recommendations on the use of biomarkers in ACS,
acute HF and chronic HF are outlined in this position statement. Healthcare providers are highly
encouraged to strive for appropriate integration of
biomarkers in clinical practice and subsequently
improve the diagnosis and prognosis of patients
with ACS and HF.
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